'Multiple Myeloma Drug Market Will Reach $9.9 Billion in 2015' Predicts Visiongain Report

'Multiple Myeloma Drug Market Will Reach $9.9 Billion in 2015' Predicts Visiongain Report PR Newswire LONDON, September 19, 2012 LONDON, September 19, 2012 /PRNewswire/ -- A new report by visiongain predicts that the world market for multiple myeloma drug sales will reach $9.9bn in 2015. That revenue forecast and others appear in World Multiple Myeloma Drug Treatment Market 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK. Visiongain forecasts that the multiple myeloma treatment market will expand rapidly with the approval of new drugs. The market is already one of the most dynamic segments in oncology, revolutionised by the 2006 approval of Celgene's Thalomid and then Revlimid, and Janssen's Velcade. In July 2012, the market reached a new milestone with the approval of Onyx's Kyprolis, a proteasome inhibitor with an improved safety profile and potential to be another blockbuster. The pharmaceutical industry analyst in visiongain, said: "The years 2012 to 2013 will see two important new products reach the market, Onyx's Kyprolis and Celgene's Actimid. Both of these have advantages over current drugs, but they're basically incremental improvements on what we already have - proteasome inhibitors and immunomodulators. "The next real shift for the market will come with the approval of newer mechanisms of action.